Concepedia

Emma Sangalang

ES

Statistics

Publications

6

Citations

546

H-Index

6

Active since

2014

Affiliations

Collaborative Drug Discovery (United States)(Current)

Emma Sangalang is an author at Collaborative Drug Discovery (United States) specializing in immunology, medicine, and immunotherapy.

ORCID

Top concepts

Publications per year

2014–2022

6

Publications

6

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

Johanna Theruvath, Marie Ménard, Benjamin Smith et al. · Nature Medicine · 2022 · 239 citations · Full text

, , +3

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

Steven E. Kauder, Tracy C. Kuo, Ons Harrabi et al. · PLoS ONE · 2018 · 164 citations · Full text

, , +18

Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity

Tracy C. Kuo, Amy Chen, Ons Harrabi et al. · Journal of Hematology & Oncology · 2020 · 69 citations · Full text

Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα

Janet Sim, Jonathan T. Sockolosky, Emma Sangalang et al. · mAbs · 2019 · 48 citations · Full text

Effectiveness of Alpha-toxin Fab Monoclonal Antibody Therapy in Limiting the Pathology of<i>Staphylococcus aureus</i>Keratitis

Armando R. Caballero, Davide Foletti, Michael A. Bierdeman et al. · Ocular Immunology and Inflammation · 2014 · 14 citations

1–5 of 6